QuidelOrtho came into this print looking like a classic deep value healthcare stock, with the share price already under pressure and the P/S ratio sitting near 0.3x. The market’s verdict on Q2 was brutal. The stock dropped about 25% in the first session after earnings, as investors focused on continued losses and balance sheet strain rather than the low headline valuation.

The headline from the quarter is clear. Reported revenue was about US$631m and adjusted EBITDA reached US$129m, yet operating cash flow stayed firmly negative and net leverage hovered near 4.3x. For a stock already pricing in a lot of bad news, the cash and debt picture is what hit hardest.

Is QuidelOrtho a rare deep value opportunity, or is this low P/S simply mirroring the balance sheet strain and persistent losses? Compare the market’s reaction with our detailed valuation analysis for QuidelOrtho

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$630.9m vs. US$613.9m (up about 3%)
• Net Income/Loss (Q2 2026 vs Q2 2025): loss of US$92.9m vs. loss of US$255.4m (loss narrowed about 64%)
• Basic EPS (Q2 2026 vs Q2 2025): loss of US$1.36 per share vs. loss of US$3.77 per share (per share loss narrowed about 64%)
• Adjusted EBITDA Margin (Q2 2026 vs Q2 2025): 20% vs. about 17% (expanded by 310 basis points, or 3.1 percentage points)

Prefer clear visuals over another dense block of earnings tables and cash flow figures? See QuidelOrtho’s full financial picture, with a focus on its balance sheet strength and debt profile, in the interactive company report for QuidelOrtho.

QuidelOrtho’s Bull Case Meets Mixed Progress

Bulls argue QuidelOrtho can turn a complex merger into a higher margin, recurring revenue machine powered by cost savings and new molecular platforms. Q2 shows part of that playbook working. Adjusted EBITDA margin reached 20%, about 3 percentage points higher than a year ago, which points to early traction from restructuring and expense discipline. Revenue outside China grew mid single digits, with Labs and Immunohematology ex China in the 3% to 9% range, which supports the idea that the core franchise can grow even as COVID testing fades.

However, the narrative also leans on cleaner cash generation and balance sheet repair. Here the evidence is weaker. Operating cash flow stayed deeply negative at US$111m, free cash flow remained negative, net leverage held around 4.3x, and management withdrew free cash flow guidance. That step signals the cash and deleveraging leg of the bull story has not yet been delivered.

Compare this margin progress and ex China growth story with how institutions are reacting. See the consensus price target analysis for QuidelOrtho

QuidelOrtho Bear Case Gets Fresh Support

The bearish view on QuidelOrtho is that high leverage, weak cash generation, and uncertainty around asset sales cap the stock’s upside even if earnings improve. This quarter largely backs that concern. Adjusted EBITDA of US$129m and a 20% margin show operating fixes are real, yet operating cash flow stayed deeply negative at US$111m and free cash flow also remained negative. The company still sits near 4.3x net leverage, with no completed point of care divestiture to fund debt reduction.

Bears also worry that guidance will keep drifting lower as COVID and respiratory testing soften and China pressures persist. Management cut full year revenue and adjusted EBITDA targets and then pulled free cash flow guidance entirely. That withdrawal is a clear missed milestone for a story that needs visible deleveraging. The near 25% share price drop since the print suggests investors are treating this as confirmation, not a temporary wobble.

After a quarter where QuidelOrtho’s leverage stayed near 4.3x and cash burn persisted, it is fair to ask whether this is just the visible part of the risk picture or if structural issues run deeper. Review the independent risk analysis for QuidelOrtho which shows 3 important warning signs

Stay Ahead With Simply Wall St

If QuidelOrtho’s low P/S ratio and recent selloff have you watching for a better entry point, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and key fundamentals. When you decide to take a position, manage QuidelOrtho alongside the rest of your holdings in the Portfolio Command Center so you only see the most important updates that matter. For a broader perspective on what other investors are seeing in this stock, tap into the Community and compare different views in one place. By spotting potential catalysts and risks early, you may improve your chances of staying one step ahead of the market.

Seeking Alternatives Beyond QuidelOrtho Now

Some stocks are building quiet breakout momentum while others are dropping off radars. You can review fresh ideas before they become widely followed, while they may still be under the radar. Consider acting promptly if appropriate for your situation.

• Identify companies with resilient balance sheets before they gain broader attention by reviewing the curated list of solid balance sheet and fundamentals stocks (49 results) for ideas that may be worth monitoring when sentiment shifts.
• Explore potential breakout moves in cash-generative AI-related companies by scanning the carefully filtered 68 profitable AI stocks that aren't just burning cash before these stories draw wider market focus.
• Evaluate income streams with yields that might complement your portfolio by assessing the hand picked 8 dividend fortresses while these payouts may still be less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.